Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes

Antiviral Therapy

Volumn 9, Issue 4, 2004, Pages 545-554

  Rullas, Joaquín ^a   Bermejo, Mercedes ^a   García Pérez, Javier ^a   Beltrán, Manuela ^a   González, Nuria ^a   Hezareh, Marjan ^b   Brown, Stephen J ^b   Alcamí, José ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b AIDS Research Alliance   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 DEOXYPHORBOL DERIVATIVE; CD4 ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2 RECEPTOR; LUCIFERASE; PHORBOL ESTER; PROSTRATIN; PROTEIN KINASE C; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VIRUS RECEPTOR;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT VIRUS INFECTION; LONG TERMINAL REPEAT; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; VIRUS ACTIVATION; VIRUS EXPRESSION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSCRIPTION;

CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HIV; HIV LONG TERMINAL REPEAT; HUMANS; LEUKOCYTES, MONONUCLEAR; NF-KAPPA B; PHORBOL ESTERS; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, HIV; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANSFECTION; VIRUS ACTIVATION;

EID: 4344587422     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S & Volberding PA. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 2002; 288:222-235.
2. Harrigan PR, Whaley M & Montaner JS. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999; 13:F59-62.
3. Blankson JN, Persaud D & Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annual Review of Medicine 2002; 53:557-593.
4. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA & Fauci AS. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of the National Academy of Sciences, USA 1997; 94:13193-13197.
5. Pomerantz RJ. Residual HIV-1 disease in the era of highly active antiretroviral therapy. New England Journal of Medicine 1999; 340:1672-1674.
6. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M & Ho DD. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. New England Journal of Medicine 1999; 340:1605-1613.
7. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J & Siliciano RF. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Medicine 1999; 5:512-517.
8. Hockett RD, Kilby JM, Derdeyn CA, Saag MS, Sillers M, Squires K, Chiz S, Nowak MA, Shaw GM & Bucy RP. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. Journal of Experimental Medicine 1999; 189:1545-1554.
9. Ho DD. Toward HIV eradication or remission: the tasks ahead. Science 1998; 280:1866-1867.
10. Fraser C, Ferguson NM, Ghani AC, Prins JM, Lange JM, Goudsmit J, Anderson RM & de Wolf F. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs. AIDS 2000; 14:659-669.
11. Stellbrink HJ, van Lunzen J, Westby M, O'Sullivan E, Schneider C, Adam A, Weitner L, Kuhlmann B, Hoffmann C, Fenske S, Aries PS, Degen O, Eggers C, Petersen H, Haag F, Horst HA, Dalhoff K, Mocklinghoff C, Cammack N, Tenner-Racz K & Racz P. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 2002; 16:1479-1487.
12. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC & Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270:1811-1815.
13. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M & Moser B. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996; 382:833-835.
14. He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S, Busciglio J, Yang X, Hofmann W, Newman W, Mackay CR, Sodroski J & Gabuzda D. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997; 385:645-649.
15. McKnight A, Wilkinson D, Simmons G, Talbot S, Picard L, Ahuja M, Marsh M, Hoxie JA & Clapham PR. Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. Journal of Virology 1997; 71:1692-1696.
16. Wu L, LaRosa G, Kassam N, Gordon CJ, Heath H, Ruffing N, Chen H, Humblias J, Samson M, Parmentier M, Moore JP & Mackay CR. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. Journal of Experimental Medicine 1997; 186:1373-1381.
17. Schols D, Struyf S, Van Damme J, Este JA, Henson G & De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. Journal of Experimental Medicine 1997; 186:1383-1388.
18. Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, Endres M, Palani A, Shapiro S, Clader JW, Greenlee WJ, Tagat JR, McCombie S, Cox K, Fawzi AB, Chou CC, Pugliese-Sivo C, Davies L, Moreno ME, Ho DD, Trkola A, Stoddart CA, Moore JP, Reyes GR & Baroudy BM. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proceedings of the National Academy of Sciences, USA 2001; 98:12718-12723.
19. Wild CT, Shugars DC, Greenwell TK, McDanal CB & Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proceedings of the National Academy of Sciences, USA 1994; 91:9770-9774.
20. Hamer DH, Bocklandt S, McHugh L, Chun TW, Blumberg PM, Sigano DM & Marquez VE. Rational design of drugs that induce human immunodeficiency virus replication. Journal of Virology 2003; 77:10227-10236.
21. Gustafson KR, Cardellina 2nd JH, McMahon JB, Gulakowski RJ, Ishitoya J, Szallasi Z, Lewin NE, Blumberg PM, Weislow OS, Beutler JA, Buckheit RW, Cragg GM, Cox PA, Bader JP & Boyd MR. A nonpromoting phorbol from the Samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. Journal of Medicinal Chemistry 1992; 35:1978-1986.
22. Szallasi Z, Krsmanovic L & Blumberg PM. Nonpromoting 12-deoxyphorbol 13-esters inhibit phorbol 12-myristate 13-acetate induced tumor promotion in CD-1 mouse skin. Cancer Research 1993; 53:2507-2512.
23. Gulakowski RJ, McMahon JB, Buckheit Jr RW, Gustafson KR & Boyd MR. Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antiviral Research 1997; 33:87-97.
24. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, Boyd MR & Pomerantz RJ. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 2001; 98:3006-3015.
25. Brooks DG, Hamer DH, Arlen PA, Gao L, Bristol G, Kitchen C, Berger EA & Zack JA. Molecular characterization, reactivation, and depletion of latent HIV. Immunity 2003; 19:413-423.
26. Korin YD, Brooks DG, Brown S, Korotzer A & Zack JA. 2002. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. Journal of Virology 76:8118-8123.
27. Bachelerie F, Alcami J, Arenzana-Seisdedos F & Virelizier JL. HIV enhancer activity perpetuated by NF-kappa B induction on infection of monocytes. Nature 1991; 350:709-712.
28. Duh EJ, Maury WJ, Folks TM, Fauci AS & Rabson AB. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proceedings of the National Academy of Sciences, USA 1989; 86:5974-5978.
29. Adachi A, Gendelman HE, Koening S, Folks T, Willey R, Rabson A & Martin MA. Production of acquired immunodeficiency syndrome-associated retrovirus in human and non-human cells transfected with an infectious molecular clone. Journal of Virology 1988; 59:284-291.
30. Arenzana-Seisdedos F, Fernandez B, Dominguez I, Jacque JM, Thomas D, Diaz-Meco MT, Moscat J & Virelizier JL. Phosphatidylcholine hydrolysis activates NF-kappa B and increases human immunodeficiency virus replication in human monocytes and T lymphocytes. Journal of Virology 1993; 67:6596-6604.
31. Northrop JP, Ullman KS & Crabtree GR. Characterization of the nuclear and cytoplasmic components of the lymphoid-specific nuclear factor of activated T cells (NFAT) complex. Journal of Biological Chemistry 1993; 268:2917-2923.
32. b promoter: enhancer-like sequences and their role in the regulation of class I gene expression. Cell 1986; 44:261-272.
33. Schwartz O, Virelizier JL, Montagnier L & Hazan U. A microtransfection method using the luciferase-encoding reporter gene for the assay of human immunodeficiency virus LTR promoter activity. Gene 1990; 88:197-205.
34. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC & Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986; 233:215-219.
35. Gomez-Gonzalo M, Carretero M, Rullas J, Lara-Pezzi E, Aramburu J, Berkhout B, Alcami J & Lopez-Cabrera M. 2001. The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals: functional roles of NF-kappaB/NFAT and SP1-binding sites in the HIV-1 long terminal repeat promoter. Journal of Biological Chemistry 276:35435-35443.
36. Bermejo M, Martin-Serrano J, Oberlin E, Pedraza MA, Serrano A, Santiago B, Caruz A, Loetscher P, Baggiolini M, Arenzana-Seisdedos F & Alcami J. Activation of blood T lymphocytes down-regulates CXCR4 expression and interferes with propagation of X4 HIV strains. European Journal of Immunology 1998; 28:3192-3204.
37. Bocklandt S, Blumberg PM & Hamer DH. Activation of latent HIV-1 expression by the potent anti-tumor promotor 12-deoxyphorbol 13-phenylacetate. Antiviral Research 2003; 59:89-98.
38. Alcami J, Lain de Lera T, Folgueira L, Pedraza MA, Jacque JM, Bachelerie F, Noriega AR, Hay RT, Harrich D, Gaynor RB, Virelizier JL & Arenzana F. Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes. EMBO Journal 1995; 14:1552-1560.
39. Witvrouw M, Pannecouque C, Fikkert V, Hantson A, Van Remoortel B, Hezareh M, De Clercq E & Brown SJ. Potent and selective inhibition of HIV and SIV by prostratin interacting with viral entry. Antiviral Chemistry & Chemotherapy 2003; 14:321-328.
40. Kulkosky J, Nunnari G, Otero M, Calarota S, Dornadula G, Zhang H, Malin A, Sullivan J, Xu Y, DeSimone J, Babinchak T, Stern J, Cavert W, Haase A & Pomerantz RJ. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. Journal of Infectious Diseases 2002; 186:1403-1411.